Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + efavirenz
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simeprevir (TMC435) is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor developed for the treatment of chronic HCV infection. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents to treat human immunodeficiency virus (HIV) infection. The combination of simeprevir and efavirenz has been studied primarily to assess pharmacokinetic interactions when co-administered, as both drugs are metabolized by the cytochrome P450 system and may affect each other's plasma concentrations[2][4]. Simeprevir inhibits viral replication by blocking the activity of the HCV NS3/4A protease, essential for viral polyprotein processing. Efavirenz inhibits HIV-1 reverse transcriptase, preventing viral RNA from being transcribed into DNA and thus halting HIV replication[8][1].
- Brand names
- OlysioSustivaStocrin
- Other names
- simeprevir + efavirenz
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on simeprevir + efavirenz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + efavirenz.